Matthias Liechti

Matthias Emanuel Liechti (born 27 May 1970) is a Swiss scientist and physician who studies psychedelics, entactogens, and other psychoactive drugs. He is the head of the Liechti Lab at the University of Basel in Switzerland. The lab conducts ''in-vitro'' research, animal studies, and clinical studies of psychoactive drugs. They have conducted clinical studies of drugs including LSD, psilocybin, mescaline, dimethyltryptamine (DMT), and MDMA. The lab also characterizes novel psychoactive substances (designer drugs).

Liechti is a professor of clinical pharmacology and internal medicine and an attending physician at the University of Basel. He attended and underwent training at the University of California, San Diego and the University Hospital of Zurich, among other institutions.

In April 2020, the Liechti Lab entered an agreement and long-term partnership with the psychedelic pharmaceutical company MindMed such that MindMed would have exclusive rights to the lab's data, compounds, and patent rights. One such project is a psychedelic "neutralizer" technology that can abort or shorten a psychedelic experience.

Uniquely in Europe, certain psychedelics and entactogens including LSD, psilocybin, and MDMA have been legal for medical use in Switzerland, where Liechti and his lab are based, since 2014. Provided by Wikipedia